Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

NCT02536742 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

NETWORK

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: Fulvestrant

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]